About Elicera

Elicera in brief Board Team Advisors Elicera's history

Immuno-oncology

What is immuno-oncology?
Oncolytic virus CAR T-cell therapy

Technology

CAR T-cell therapy Challenges Mode-of-action Scientific publications

Pipeline

Pipeline ELC-100 ELC-201 ELC-301 ELC-401 Clinical trials Patent portfolio

Investors

Press Releases Corporate Governance the Share Financial Reports Financial Calendar Events IPO Analyst Coverage

The Share

Elicera Therapeutics is listed on Nasdaq First North Growth Market. The company has issued one class of shares and the total number of shares amounts to 19 782 000.

Trading information

The Share

‍Short name: ELIC
ISIN-code: SE0015382080

List of 10 largest shareholders in Elicera as of December 31, 2022

Name

Capital/Votes, %

Magnus Essand

3 314 475

16,8

Di Yu

3 312 600

16,8

Jamal El-Mosleh

2 700 000

13,7

Nordnet

1 304 063

6,6

Six Sis AG

738 600

3,7

Avanza

660 703

3,3

Göran Persson

336 530

1,7

Kaj Rintala

230 000

1,2

Lars Blihagen

191 423

1,0

Agneta Edberg

120 291

0,6

Others

6 873 315

34,7

Total

19 782 000

100

Elicera Therapeutics AB is a clinical stage immuno-oncology company developing cell and gene therapies for immune-based cancer treatments.

Elicera Therapeutics AB (publ)
World Trade Center Göteborg
Mässans gata 10, floor 7
412 51, Göteborg
info@elicera.com
+46 (0)70-331 90 51‬

Org.nr: 556966-4955

Integrity Policy

By continuing to browse this website you agree to cookies being stored on your device in order to improve the experience and analyze how it is being used. Read more in our Integrity policy.

Deny Accept